Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7132-7141

  Řezáčová, Pavlína ^a,b   Pokorná, Jana ^a,c   Brynda, Jiří ^a,b   Kožíšek, Milan ^a,c   Cígler, Petr ^a,d   Lepšík, Martin ^a   Fanfrlík, Jindřich ^a   Řezáč, Jan ^a   Šašková, Klára Grantz ^a,c   Sieglová, Irena ^a,b   Plešek, Jaromír ^e   Šícha, Václav ^e   Grüner, Bohumír ^e   Oberwinkler, Heike ^f   Sedláček', Juraj ^b   Kräusslich, Hans Georg ^f   Hobza, Pavel ^a   Král, Vladimír ^d   Konvalinka, Jan ^a,b,c  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

^e INSTITUTE OF INORGANIC CHEMISTRY   (Czech Republic)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; CARBORANE DERIVATIVE; COBALT; PROTEINASE INHIBITOR; SODIUM DIETHYLIMINO BIS 8,8 [5 (3 OXA PENTOXY) 3 COBALT BIS (1,2 DICARBOLLIDE)]DIATE; SODIUM HYDROGEN 2 HYDROXYETHYLIMINO BIS 8,8 [5 (3 OXAPENTOXY) 3 COBALT BIS(1,2 DICARBOLLIDE)]DIATE; SODIUM HYDROGEN 3 COBALT BIS(1,2 DICARBOLLID)MU 8,8' YL IMINO BIS 8,8 [5 (3 OXA PENTOXY) 3 COBALT BIS(1,2 DICARBOLLIDE)]DIATE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

BORON COMPOUNDS; CARBON; COBALT; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ELECTRONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MODELS, MOLECULAR; MOLECULAR CONFORMATION;

EID: 71049176193     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9011388     Document Type: Article

References (42)

1. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A 1988, 85, 4686-4690.
2. Mastrolorenzo, A.; Rusconi, S.; Scozzafava, A.; Barbaro, G.; Supuran, C. T. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr. Med. Chem. 2007, 14, 2734-2748.
3. Condra, J. H.; Schleif, W. A.; Blahy, O. M.; Gabryelski, L. J.; Graham, D. J.; Quintero, J. C.; Rhodes, A.; Robbins, H. L.; Roth, E.; Shivaprakash, M.; et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374, 569-571.
4. Cigler, P.; Kozisek, M.; Rezacova, P.; Brynda, J.; Otwinowski, Z.; Pokorna, J.; Plesek, J.; Gruner, B.; Doleckova-Maresova, L.; Masa, M.; Sedlacek, J.; Bodem, J.; Krausslich, H. G.; Kral, V.; Konvalinka, J. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. U.S.A 2005, 102, 15394-15399.
5. Grimes, R. N. Metallacarboranes in the new millennium. Coord. Chem. Rev. 2000, 200, 773-811.
6. King, R. B. Three-dimensional aromaticity in polyhedral boranes and related molecules. Chem. Rev. 2001, 101, 1119-1152.
7. Chen, Z. F.; King, R. B. Spherical aromaticity: Recent work on fullerenes, polyhedral boranes, and related structures. Chem. Rev. 2005, 105, 3613-3642.
8. Lesnikowski, Z. J.; Paradowska, E.; Olejniczak, A. B.; Studzinska, M.; Seekamp, P.; Schussler, U.; Gabel, D.; Schinazi, R. F.; Plesek, J. Towards new boron carriers for boron neutron capture therapy: metallacarboranes and their nucleoside conjugates. Bioorg. Med. Chem. 2005, 13, 4168-4175.
9. Sivaev, I. B.; Bregadze, V. V. Polyhedral Boranes for Medical Applications: Current Status and Perspectives. Eur. J. Inorg. Chem. 2009, 1433-1450.
10. Plesek, J. Potential Applications of the Boron Cluster Compounds. Chem. Rev. 1992, 92, 269-278.
11. Olejniczak, A. B.; Plesek, J.; Kriz, O.; Lesnikowski, Z. J. A nucleoside conjugate containing a metallacarborane group and its incorporation into a DNA oligonucleotide. Angew. Chem., Int. Ed. 2003, 42, 5740-5743.
12. Beatty, B. G.; Paxton, R. J.; Hawthorne, M. F.; Williams, L. E.; Rickard-Dickson, K. J.; Do, T.; Shively, J. E.; Beatty, J. D. Pharmacokinetics of an anti-carcinoembryonic antigen monoclonal antibody conjugated to a bifunctional transition metal carborane complex (venus flytrap cluster) in tumor-bearing mice. J. Nucl. Med. 1993, 34, 1294-1302.
13. Paxton, R. J.; Beatty, B. G.; Hawthorne, M. F.; Varadarajan, A.; Williams, L. E.; Curtis, F. L.; Knobler, C. B.; Beatty, J. D.; Shively, J. E. A transition metal complex (Venus flytrap cluster) for radioimmunodetection and radioimmunotherapy. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 3387-3391.
14. Kozisek, M.; Cigler, P.; Lepsik, M.; Fanfrlik, J.; Rezacova, P.; Brynda, J.; Pokorna, J.; Plesek, J.; Gruner, B.; Grantz Saskova, K.; Vaclavikova, J.; Kral, V.; Konvalinka, J. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. J. Med. Chem. 2008, 51, 4839-4843.
15. 12(-) Ion to the 9-R2s-Ch2-7,8-C2b9h11 Zwitterions by Formaldehyde and Dialkyl Sulfides - General Synthesis of the Compounds 10-R2e-7,8-C2b9h11 (E=O,S). Collect. Czech. Chem. Commun. 1993, 58, 1534-1547.
16. Stogniy, M. Y.; Abramova, E. N.; Lobanova, I. A.; Sivaev, I. B.; Bragin, V. I.; Petrovskii, P. V.; Tsupreva, V. N.; Sorokina, O. V.; Bregadze, V. I. Synthesis of functional derivatives of 7,8-dicarbanido-undecaborate anion by ring-opening of its cyclic oxonium derivatives. Collect. Czech. Chem. Commun. 2007, 72, 1676-1688.
17. Lineweaver, H.; D., B. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 1934, 56, 656-666.
18. Gulnik, S. V.; Suvorov, L. I.; Liu, B.; Yu, B.; Anderson, B.; Mitsuya, H.; Erickson, J. W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34, 9282-9287.
19. Betts, M. J.; Sternberg, M. J. E. An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng. 1999, 12, 271-283.
20. Fanfrlik, J.; Brynda, J.; Rezac, J.; Hobza, P.; Lepsik, M. Interpretation of protein/ligand crystal structure using QM/MM calculations: case of HIV-1 protease/metallacarborane complex. J. Phys. Chem. B 2008, 112, 15094-15102.
21. Selucky, P.; Plesek, J.; Rais, J.; Kyrs, M.; Kadlecova, L. Extraction of Fission-Products into Nitrobenzene with Dicobalt Tris-Dicarbollide and Ethyleneoxy-Substituted Cobalt Bis-Dicarbollide. J. Radioanal. Nucl. Chem. 1991, 149, 131-140.
22. Plesek, J.; Hermanek, S.; Franken, A.; Cisarova, I.; Nachtigal, C. Dimethyl sulfate induced nucleophilic substitution of the [bis(1,2-dicarbollido) -3-cobalt(1-)]ate ion. Syntheses, properties and structures of its 8,8′-mu-sulfato, 8-phenyl and 8-dioxane derivatives. Collect. Czech. Chem. Commun. 1997, 62, 47-56.
23. Semioshkin, A. A.; Sivaev, I. B.; Bregadze, V. I. Cyclic oxonium derivatives of polyhedral boron hydrides and their synthetic applications. Dalton Trans. 2008, 977-992.
24. Kubat, P.; Lang, K.; Cigler, P.; Kozisek, M.; Matejicek, P.; Janda, P.; Zelinger, Z.; Prochazka, K.; Kral, V. Tetraphenylporphyrincobalt(III) bis(1,2-dicarbollide) conjugates: from the solution characteristics to inhibition of HIV protease. J. Phys. Chem. B 2007, 111, 4539-4546.
25. Matejicek, P.; Cigler, P.; Prochazka, K.; Kral, V. Molecular assembly of metallacarboranes in water: light scattering and microscopy study. Langmuir 2006, 22, 575-581. (Pubitemid 43164792)
26. Gruner, B.; Mikulasek, L.; Baca, J.; Cisarova, I.; Bohmer, V.; Danila, C.; Reinoso-Garcia, M. M.; Verboom, W.; Reinhoudt, D. N.; Casnati, A.; Ungaro, R. Cobalt bis(dicarbollides)(1-) covalently attached to the calix[4]arene platform: The first combination of organic bowl-shaped matrices and inorganic metallaborane cluster anions. Eur. J. Org. Chem. 2005, 2022-2039.
27. Gruner, B.; Plzák, Z. J. Chromatogr., A 1997, 789, 497-517.
28. Weber, J.; Mesters, J. R.; Lepsik, M.; Prejdova, J.; Svec, M.; Sponarova, J.; Mlcochova, P.; Skalicka, K.; Strisovsky, K.; Uhlikova, T.; Soucek, M.; Machala, L.; Stankova, M.; Vondrasek, J.; Klimkait, T.; Kraeusslich, H. G.; Hilgenfeld, R.; Konvalinka, J. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J. Mol. Biol. 2002, 324, 739-754.
29. Vaclavikova, J.; Weber, J.; Machala, L.; Reinis, M.; Linka, M.; Bruckova, M.; Vandasova, J.; Stankova, M.; Konvalinka, J. Longterm analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression. Acta Virol. 2005, 49, 29-36. (Pubitemid 47046831)
30. Mildner, A. M.; Rothrock, D. J.; Leone, J. W.; Bannow, C. A.; Lull, J. M.; Reardon, I. M.; Sarcich, J. L.; Howe, W. J.; Tomich, C. S.; Smith, C. W.; et al. The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 1994, 33, 9405-9413.
31. Williams, J. W.; Morrison, J. F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 1979, 63, 437-467.
32. Minor, W.; Cymborowski, M.; Otwinowski, Z.; Chruszcz, M. HKL-3000: the integration of data reduction and structure solution; from diffraction images to an initial model in minutes. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 859-866.
33. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
34. Vagin, A.; Teplyakov, A. An approach to multi-copy search in molecular replacement. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2000, 56, 1622-1624.
35. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255.
36. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
37. Winn, M. D.; Isupov, M. N.; Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2001, 57, 122-133.
38. Lovell, S. C.; Davis, I. W.; Arendall, W. B., III; de Bakker, P. I.; Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 2003, 50, 437-450.
39. De Lano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC: San Carlos, CA; http://www.pymol.org.
40. Krissinel, E.; Henrick, K. Detection of Protein Assemblies in Crystals. In CompLife 2005, LNBI 3695; Springer-Verlag: Berlin Heidelberg, 2005; pp 163-174.
41. Jones, D. T.; Taylor, W. R.; Thorton, J. M. A Model Recognition Approach to the Prediction of All-Helical Membrane-Protein Structure and Topology. Biochemistry 1994, 33, 3038-3049.
42. Brunger, A. T. Free R-Value - A Novel Statistical Quantity for Assessing the Accuracy of Crystal Structures. Nature 1992, 355, 472-475.